AI trial matching: Tempus TIME vs Trialbee vs Leal

Choose the route from a patient to a trial

A matching result is useful only if someone can act on it. Tempus TIME, Trialbee Honey, and Leal Health connect patient information to clinical-trial opportunities through different workflows. This comparison addresses potential eligibility and recruitment pathways, rather than literature search. These products are adjacent choices, not identical replacements: an oncology practice, study sponsor, and individual patient enter the process at different points.

Tempus TIME

Tempus TIME combines patient matching with an oncology trial network and support for activating studies at participating sites. The provider offering uses large language models and machine learning with clinical expertise to pre-screen potential matches from structured and unstructured notes. A clinical team presents potentially eligible patients to the site, while patient summaries and study insights support the research workflow. That gives an oncology practice a route from evidence in its records toward an actionable research opportunity. TIME’s Just-in-Time model connects the match to site activation, and the TIME Precision Network extends the program to Phase I-capable investigators. The network element matters: locating a candidate for a trial and making that trial available locally are related but different tasks. Tempus suits oncology centers seeking both matching support and a broader research portfolio. Its scope follows the participating site and protocol; a candidate identified by the platform still needs the study’s screening and consent process.

Trialbee Honey

Trialbee Honey organizes the recruitment journey from initial interest through pre-qualification and site referral. It centralizes candidates arriving through advocacy groups, advertising, referral networks, and other channels, making their progress visible to sponsors, CROs, and site staff. Protocol-specific questionnaires support initial screening, while secondary assessment checks the details before referral. Trialbee’s September 15, 2026 launch adds an AI Pre-Screening Agent that lets patients complete that assessment conversationally or request a call with an experienced nurse. The agent is grounded in approved study content and protocol criteria, answering practical questions and escalating those outside its scope. Candidate summaries bring assessment details, activity, and nurse notes into one view. Honey suits study teams whose main difficulty is converting interest into relevant, traceable referrals. Its dashboard also helps explain where candidates leave the process or fail qualification. This is a recruitment and pre-screening workflow, rather than a promise to determine final enrollment independently.

Leal Health

Leal Health offers a patient and clinician route into oncology treatment and trial discovery. Its clinician-facing page describes NLP matching against inclusion and exclusion criteria, connected to ClinicalTrials.gov. A patient selects a cancer type and completes a questionnaire to receive a personalized list of treatment options, while the support team helps explain next steps. The service includes advanced treatment discovery as well as clinical trials, so its output should not be interpreted as a list containing only research studies. Leal suits an oncologist or patient wanting to explore options beyond those immediately visible at one treatment center. It is a supplementary decision-support and navigation service, with a free patient matching proposition, rather than a substitute for the site’s recruitment operations. Its cancer focus and supported diagnosis coverage matter. A potential match can start a discussion with the clinical team, but it does not resolve the trial’s complete eligibility criteria, local availability, or enrollment decision.

Where the patient information comes from

Tempus TIME screens clinical records in a provider workflow and combines that process with expert pre-screening. Trialbee Honey starts from candidates arriving through recruitment channels and qualifies them against a particular study. Leal creates a patient-facing route into cancer-specific discovery, which clinicians can also use. For an oncology practice searching its own population, Tempus’s records-based workflow is relevant. For a sponsor coordinating referrals from several sources, Honey centralizes the candidate journey. For someone seeking a broader set of possible treatment discussions, Leal lowers the access barrier. Each starts with a different relationship to the patient and the research team.

How a match becomes a next step

Tempus TIME connects patient identification with trial activation at participating sites, including its Phase I network. Trialbee Honey gives site staff a pre-qualified referral and tracks contact, eligibility progress, and screening activity. Leal gives the patient and oncologist options and navigation support that can lead to contact with a trial team. A practice wanting to build its research capability may therefore value TIME’s network role. A study team improving candidate handoffs may value Honey’s structured workflow. A patient seeking options may value Leal’s direct entry point. These differences explain why free discovery and institutional recruitment should not be compared as equivalent purchases.

Commercial access and the enrollment boundary

Tempus TIME and Trialbee Honey use scoped commercial conversations, with numeric fees and billing intervals unconfirmed. Leal describes patient treatment matching as free; that does not establish a free enterprise recruitment platform or payment for trial participation costs. The relevant comparison includes the institution’s site/network scope, recruitment services, and AI-agent access. Across all three, matching and pre-qualification support the next clinical conversation. Final eligibility, consent, and enrollment remain part of the trial’s own process rather than an outcome established by a software suggestion.

Which should you choose?

Consider Tempus TIME for oncology matching tied to trial-network participation, Trialbee Honey for study-specific candidate qualification and referral operations, and Leal for patient and clinician discovery. Choose the route that addresses the missing step between a possible match and an actionable trial opportunity.